The total number of records retrieved from this search are 30. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_3237	Virus nameHerpes simplex virus	Virus strainwild type	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.0001 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3238	Virus nameHerpes simplex virus	Virus strainwild type	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.001 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3239	Virus nameHerpes simplex virus	Virus strainwild type	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.01 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3240	Virus nameHerpes simplex virus	Virus strainwild type	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.1 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3241	Virus nameHerpes simplex virus	Virus strainwild type	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration1 MOI	In-vitro result90% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3242	Virus nameHerpes simplex virus	Virus strainwild type	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration10 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3243	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.0001 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3244	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.001 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3245	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.01 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3246	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.1 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3247	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration1 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3248	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration10 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3249	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.0001 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3250	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.001 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3251	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.01 MOI	In-vitro result75% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3252	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.1 MOI	In-vitro result72% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3253	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration1 MOI	In-vitro result60% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3254	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration10 MOI	In-vitro result55% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3255	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.0001 MOI	In-vitro result77% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3256	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.001 MOI	In-vitro result60% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3257	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.01 MOI	In-vitro result52% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3258	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.1 MOI	In-vitro result48% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3259	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration1 MOI	In-vitro result30% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3260	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration10 MOI	In-vitro result25% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3261	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.0001 MOI	In-vitro result40% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3262	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.001 MOI	In-vitro result40% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3263	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.01 MOI	In-vitro result27% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3264	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.1 MOI	In-vitro result22% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3265	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration1 MOI	In-vitro result20% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3266	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration10 MOI	In-vitro result10% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891